Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

Phase 4

Completed

Conditions: Cryptogenic Sensory Polyneuropathy

Interventions: Drug: Nortriptyline
Drug: Mexiletine
Drug: Duloxetine
Drug: Pregabalin

Registration Number: NCT02260388

Lead Sponsor: University of Kansas Medical Center

Brief Summary: The purpose of this large comparative effectiveness study led by Richard J. Barohn, MD, of the University of Kansas Medical Center, is to learn about the safety and effectiveness of nortriptyline, duloxetine, pregabalin and mexiletine in treating cryptogenic sensory polyneuropathy (CSPN).

Detailed Description: The goal of this research project is to find the best drug for the treatment of pain in patients with CSPN. While the pharmaceutical industry has focused attention on drugs for treating diabetic sensory neuropathy (DSPN), and two drugs are now FDA approved, there have not been any prospective trials in CSPN. And, because there are no studies with CSPN patients, insurance carriers often reject authorizing prescriptions for some drugs for patients with CSPN.

There are four drugs that will be tested in this study: nortriptyline, duloxetine, pregabalin and mexiletine. These drugs are not approved by the FDA for the treatment of CSPN and are considered "investigational" in this study.

There are two periods in this study: Screening/Baseline and Study Drug. During the Screening/Baseline period the researchers will determine eligibility for potential subjects. During the second period, eligible patients who consented to participate will take the study drug. Participants will be randomized to receive one of the four drugs in this study. Participants will know which drug they are taking. Participants will not be allowed to switch groups and receive a different drug during the study.

This study uses an adaptive study design. This means the study can enroll less participants and provide better conclusions. The study design allows the researchers the ability to make changes to the approach of the study or to stop the study early if there are strong results.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 402

Inclusion Criteria

Diagnosis of cryptogenic sensory polyneuropathy.
Likert Pain Score of greater than or equal to 4.
Must not currently be on nortriptyline, duloxetine, pregabalin or mexiletine or similar class of medication for at least 7 days from baseline study visit.

Exclusion Criteria

Any medical condition or current medication that would prevent them from taking either nortriptyline, duloxetine, pregabalin or mexiletine.
Unable to give consent.
Unable or not willing to comply with the study.
Other causes for polyneuropathy.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Nortriptyline	Nortriptyline	Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
Mexiletine	Mexiletine	Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
Duloxetine	Duloxetine	Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
Pregabalin	Pregabalin	Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.

Primary Outcome Measures

Name	Time	Method
Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit	12 weeks	The final outcome of the study is a combination of two endpoints, efficacy and quit or treatment discontinuation rates. The first endpoint was a patient responder-defined measure of efficacy. A patient was deemed efficacious if a 50% or more reduction was observed in the Likert pain-scale from the baseline visit to the 12 week visit (i.e. 6 at baseline to 3 or less at week 12). The second endpoint was the observed percentage of patients who discontinued treatment prior to the last follow up visit for any reason or were lost to follow up. The utility function, which combines efficacy and quit rates, was used to drive the adaptive randomization, stopping criteria, and final analysis conclusions.

Secondary Outcome Measures

Name	Time	Method
SF12 Health Composite Scores	12 weeks	SF-12v2® Health Survey Standard The Optum™ SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view. Survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores. Scores are calibrated so that 50 is the average score or norm, standard deviation = 10. Higher scores indicate better health for both mental and physical component summary scores.
PROMIS Pain Interference Short Form v1.0 8a T Score	12 weeks	Higher scores for pain interference represents worse outcome (more pain interference) T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.
PROMIS Fatigue Short Form v1.0 8a	12 Weeks	Higher scores for fatigue represents worse outcome (more fatigue). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.
PROMIS Sleep Disturbance Short Form v1.0 8a	12 weeks	Higher scores for sleep disturbance represents worse outcome (more sleep disturbance). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population. Higher scores equals more of the concept being measured

Trial Locations

Locations (46): Barrow Neurological Institute
🇺🇸
Phoenix, Arizona, United States
Phoenix Neurological Associates
🇺🇸
Phoenix, Arizona, United States
Cedars-Sinai Medical Center
🇺🇸
Los Angeles, California, United States
California Pacific Medical Center
🇺🇸
San Francisco, California, United States
University of California San Francisco
🇺🇸
San Francisco, California, United States
University of Colorado Denver Anschutz Campus
🇺🇸
Aurora, Colorado, United States
Colorado Springs Neurological Associates
🇺🇸
Colorado Springs, Colorado, United States
University of Florida - Gainesville
🇺🇸
Gainesville, Florida, United States
University of Florida Health Science Center - Jacksonville
🇺🇸
Jacksonville, Florida, United States
University of Miami Miller School of Medicine
🇺🇸
Miami, Florida, United States
Scroll for more (36 remaining)
Barrow Neurological Institute
🇺🇸Phoenix, Arizona, United States